Presidio Medical

Presidio Medical is a private, clinical-stage medical device company pioneering a new approach to neuromodulation for chronic nociceptive pain. Its core technology, the Ultra Low Frequency (ULF™) Neuromodulation System, is designed to inhibit neuronal activity at the pain site, offering a potential therapeutic option for a large patient population underserved by current neuropathic pain-focused devices. Led by a seasoned management team with deep experience from companies like Boston Scientific, Abbott, and Alcon, the company is positioned to address a significant unmet need in the chronic pain market. Presidio is currently in the development and clinical validation stage, building its team and advancing its technology toward commercialization.

Ultra Low Frequency (ULF™) Neuromodulation System designed to inhibit neuronal responses for treating chronic nociceptive pain and other diseases of undesired neural activity.

Presidio competes in the broad neuromodulation market dominated by large players like Medtronic, Boston Scientific, and Abbott, but its specific focus on nociceptive pain creates a differentiated niche. Its primary competition comes from existing pain management options (e.g., opioids, NSAIDs, injections, physical therapy) and other device-based therapies not optimized for nociceptive mechanisms.